CC & C was honored to be one of the 3 high-tech start-ups selected in the 2017 NETVA program. As a reminder, NETVA, for New Technology Venture Accelarator, is a program sponsored by the French Embassy in Washington to develop scientific and industrial exchanges between different regions of the United States and the French ecosystem of innovative start-ups.

Therefore, a member of the consulate has taken charge of Chief Scientific Officer of CC & C, Rémy Brossel, for a week during his trip to San Francisco and the Bay Area, the heart of the innovation zone in the field of medtechs.

Once again we could check on the spot the wealth of the Californian ecosystem, in all areas: financial wealth, of course, but also wealth of infrastructure, curiosity, incredible combination of talent from around the world, etc. Within a week, on a Bay Area that is large like a French department, we were able to navigate between Universities (UCSF, Stanford, Berkeley), Venture Capitalists of Silicon Valley, Oakland and San Jose start-ups, and San Francisco incubators.

From meeting to meeting, making contact with each other, Rémy Brossel finally got to know a French physicist, Professor at Stanford, and convince him to take part in the animal experimentation we need so much: for the record we need to prove the action of a stress field on a cancer of human pancreas grafted in a mouse pancreas. The icing on the cake, this fellow physicist showed us, in the basement of Stanford, a copy of the field gradient generator that we would need. We thought we would have to develop a prototype as part of a European experiment, the plans are ready, the estimates are quantified, and now we discover that the prototype already exists! This instrument was developed by a California start-up for imaging purposes, but an opening to the therapeutic field would be a powerful growth driver for them.

Obviously, such opportunities are not to be overlooked, so we are at work to mount this experiment on the Pacific Rim, even if regulatory, legal and financial obstacles are not trivial. However, the subsidies of the National Cancer Institute (NCI) are very abundant, so we are hopeful, especially as we enjoy the active support of our institutional partners here (Eurobiomed, ARII PACA) and there (San Consulate Francisco and FrenchTechHub) …

In addition, contacts were made with investors (true to their reputation to be less allergic to risk than their French counterparts…), which follow the emergence of our American subsidiary with impatience …

Next step: We are invited to return to Stanford, with the support of the France-Stanford Center, to present our technology to an academic board by the second half of 2018.

To be continued…